"Centralized procurement of intraocular lenses has been implemented for many rounds, which basically meets all the commonly used varieties in hospitals, and with the continuous enrichment of varieties, it also gradually meets the planting needs of different patients." On December 1, Zhu Siquan, deputy dean of the School of Ophthalmology of Capital Medical University, told the people's ** health client reporter that clinically, the centralized procurement of high-value medical consumables has greatly improved the accessibility of cataract patients who need to receive lens implantation.
On November 30, the fourth batch of state-organized high-value medical consumables centralized procurement was opened in Tianjin, resulting in the proposed winning results. According to the Health Insurance Bureau, the average price of the selected products in this centralized procurement is about 70%, of which the average price of intraocular lens consumables is reduced by 60%, which is expected to save 3.9 billion yuan per year, and the average price of sports medicine consumables is 74%, which is expected to save 6.7 billion yuan per year.
This centralized procurement covers intraocular lenses, sports medicine-related high-value medical consumables.
According to the calculation before centralized procurement, the market size of the centralized procurement products is about 15.5 billion yuan, including 6.5 billion yuan for 11 varieties of intraocular lens consumables and 9 billion yuan for 19 varieties of sports medicine consumables. This collection benefits a wide range of cataract patients who have undergone lens implantation, as well as patients who need sports medicine surgery due to labor and sports muscle and ligament damage.
From the perspective of intraocular lenses alone, Zhu Siquan said, "After the intraocular lens enters the centralized procurement, the biggest performance is a significant decline, and some trifocal lenses that were close to 20,000 yuan before only need 8,000-9,000 yuan through centralized procurement, so the acceptance of patients is improving." ”
According to the official WeChat message of the National Health Insurance Administration, from August 29 to 30, 2023, Shi Zihai, member of the Party Group and deputy director of the National Health Insurance Administration, pointed out that it is necessary to adhere to the "one product and one policy", improve the procurement rules, and carry out the fourth batch of high-value medical consumables centralized procurement organized by the state with high quality.
'One product and one policy' is very suitable for the centralized procurement of high-value medical consumables, because the needs of patients are becoming more and more diverse. We have to admit the fact that the level of the crystal is positively correlated, and the centralized procurement only plays a role in lowering the quality, but the quality of the crystal will still be graded, and one product and one policy can be well adapted to this feature, so that different hospitals and different patients can choose their own affordable products. Zhu Siquan introduced.
According to the National Health Insurance Administration, in the next step, the National Health Insurance Administration will work with relevant departments to guide all localities and selected enterprises to do a good job in the implementation of the selection results, so as to ensure that patients across the country can use the selected products after the price reduction from May to June 2024.